Circulating biomarkers from tumour bulk to tumour machinery: Promises and pitfalls

European Journal of Cancer

Volumn 40, Issue 17 SPEC. ISS., 2004, Pages 2613-2622

  Gion, M ^a   Daidone, M G ^b  

^a Ospedale Civile   (Italy)

^b Ist Naz Stud Cura Tumori M

Author keywords

Biomarkers; Cancer; Classification; Pitfalls

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; CYCLIN D1; DEATH ASSOCIATED PROTEIN KINASE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P53; PROTEIN P73; SOMATOMEDIN; STEROID HORMONE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN; VASCULOTROPIN;

CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RISK; DIAGNOSTIC VALUE; DNA POLYMORPHISM; GENE MUTATION; HUMAN; MLH1 GENE; MSH GENE; MUC1 GENE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 8444222365     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.07.031     Document Type: Article

References (88)

1. D.W. Chan, and M.K. Schwartz Tumour markers: introduction and general principles E.P. Diamandis H.A. Fritsche H. Lilja D.W. Chan M.K. Schwartz Tumor markers: physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington, DC 9 19
2. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
3. M. Gion, and G. Gasparini Biomarkers as therapeutic targets: toward personalized treatments in oncology E.P. Diamandis H.A. Fritsche H.A. Lilja H. Lilja D.W. Chan M.K. Schwartz Tumor markers: physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington, DC 151 162
4. Organization for Economic Cooperation and Development (OECD). Genetic testing policy issues for the next millennium: abstract of remarks. J Bio law Bus 2001, 4(3), 37-50
5. P.T. Iau, R.D. Macmillan, and R.W. Blamey Germ line mutations associated with breast cancer susceptibility Eur J Cancer 37 3 2001 300 321
6. G.M. Petersen, J.D. Brensinger, K.A. Johnson, and F.M. Giardiello Genetic testing and counseling for hereditary forms of colorectal cancer Cancer 86 11 Suppl 1999 2540 2550
7. New York State Department of Health. Genetic susceptibility to breast and ovarian cancer: assessment, counselling and testing guideline. American College of Medical Genetics Foundation, 1999. Available from: 〈 www.health.state.ny.us/nysdoh/search/index.htm 〉
8. T.R. Rebbeck, H.T. Lynch, S.L. Neuhausen, S.A. Narod, L. Van't Veer, and J.E. Garber Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl J Med 346 21 2002 1616 1622
9. N.D. Kauff, J.M. Satagopan, M.E. Robson, L. Scheuer, M. Hensley, and C.A. Hudis Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation N Engl J Med 346 21 2002 1609 1615
10. T.J. Key, P.N. Appleby, G.K. Reeves, A. Roddam, J.F. Dorgan, and C. Longcope Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women J Natl Cancer Inst 95 16 2003 1218 1226
11. E. Giovannucci Insulin-like growth factor-I and binding protein-3 and risk of cancer Horm Res 51 1999 34 41
12. A. Decensi, C. Robertson, and B. Ballardini Effect of tamoxifen on lipoprotein (a) and insulin-like growth factor-I (IGF-I) in healthy women Eur J Cancer 35 1999 596 600
13. B.L. Powell, D. Piersma, M.E. Kevenaar, I.L. van Staveren, A.P. Themmen, and B.J. Iacopetta Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset J Clin Endocrinol Metab 88 4 2003 1653 1657
14. S. Wedren, T.R. Rudqvist, F. Granath, E. Weiderpass, M. Ingelman-Sundberg, and I. Persson Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk Carcinogenesis 24 4 2003 681 687
15. J.F.R. Robertson, W. Jaeger, and J.J. Syzmendera The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers Eur J Cancer 35 1999 47 53
16. R.T. Vollmer, N.A. Dawson, and N.J. Vogelzang The dynamics of prostate specific antigen in hormone refractory prostate carcinoma Cancer 83 1998 1989 1994
17. N.A. Dawson Response criteria in prostatic carcinoma Semin Oncol 26 1999 174 184
18. K.L. Cheung, C.R.L. Graves, and J.F.R. Robertson Autoantibodies as circulating cancer markers E.P. Diamandis H.A. Fritsche H. Lilja D.W. Chan M.K. Schwartz Tumor markers: physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington, DC 123 133
19. Y. Hirasawa, N. Kohno, A. Yokoyama, K. Kondo, K. Hiwada, and M. Miyake Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer Am J Respir Crit Care Med 161 2 Pt 1 2000 589 594
20. l. Yip, and R.L. Ward Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines Cancer Immunol Immunother 50 2002 569 587
21. T. Soussi p53 Antibodies in the sera of patients with various types of cancer: a review Cancer Res 60 2000 1777 1788
22. C. Sturgeon Practice guidelines for tumor marker use in the clinic Clin Chem 48 8 2002 1151 1159
23. H. Lilja, J. Oldbring, G. Rannevik, and C.B. Laurell Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen J Clin Invest 80 1987 281 285
24. A.H. Fortier, J.W. Holaday, H. Liang, C. Dey, D.K. Grella, and J. Holland-Linn Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo Prostate 56 3 2003 212 219
25. C. Akewanlop, M. Watanabe, B. Singh, M. Walker, D.W. Kufe, and D.F. Hayes Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody Cancer Res 61 10 2001 4061 4065
26. P. Maxwell Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker Br J Biomed Sci 56 3 1999 209 214
27. A. Ziegler, U. Zangemeister-Wittke, and R.A. Stahel Circulating DNA: a new diagnostic gold mine Cancer Treat Rev 28 2002 255 271
28. M. Stroun, J. Lyautey, C. Lederrey, A. Olson-Sand, and P. Anker About the possible origin and mechanism of circulating DNA apoptosis and active DNA release Clin Chim Acta 313 2001 139 142
29. D.A. Ahlquist, J.E. Skoletsky, K.A. Boynton, J.J. Harrington, D.W. Mahoney, and W.E. Pierceall Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel Gastroenterology 119 2000 1219 1227
30. G. Sozzi, D. Conte, M. Leon, R. Ciricione, L. Roz, and C. Ratcliffe Quantification of free circulating DNA as a diagnostic marker in lung cancer J Clin Oncol 21 2003 3902 3908
31. C. Arciero, S.B. Somiari, C.D. Shriver, H. Brzeski, R. Jordan, and H. Hu Functional relationship and gene ontology classification of breast cancer biomarkers Int J Biol Markers 18 4 2003 241 272
32. R.S. Negm, M. Verma, and S. Srivastava The promise of biomarkers in cancer screening and detection Trends Mol Med 8 2002 288 293
33. D. Sidransky, A. Von Eschenbach, Y.C. Tsai, P. Jones, I. Summerhayes, and F. Marshall Identification of p53 gene mutations in bladder cancers and urine samples Science 252 1991 706 709
34. D. Sidransky, T. Tokino, S.R. Hamilton, K.W. Kinzler, B. Levin, and P. Frost Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors Science 256 1992 102 105
35. S.D. Smith, M.A. Wheeler, J. Plescia, J.W. Colberg, R.M. Weiss, and D.C. Altieri Urine detection of survivin and diagnosis of bladder cancer J Am Med Assoc 285 2001 324 328
36. A.P. Feinberg Cancer epigenetics takes center stage Proc Natl Acad Sci USA 98 2001 392 394
37. P.A. Jones, and P.W. Laird Cancer epigenetics comes of age Nat Genet 21 1999 163 167
38. C.A. Eads, R.V. Lord, K. Wickramasinghe, T.I. Long, S.K. Kurumboor, and L. Bernstein Epigenetic patterns in the progression of esophageal adenocarcinoma Cancer Res 61 2001 3410 3418
39. M. Esteller, A. Sparks, M. Toyota, M. Sanchez-Cespedes, G. Capella, and M.A. Peinado Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer Cancer Res 60 2000 4366 4371
40. J.P. Issa The epigenetics of colorectal cancer Ann NY Acad Sci 910 2000 140 153
41. K. Kawakami, J. Brabender, R.V. Lord, S. Groshen, B.D. Greenwald, and M.J. Krasna Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma J Natl Cancer Inst 92 2000 1805 1811
42. A. Bearzatto, D. Conte, M. Frattini, N. Zaffaroni, F. Andriani, and D. Balestra p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer Clin Cancer Res 8 2002 3782 3787
43. F. Andriani, D. Conte, T. Mastrangelo, M. Leon, C. Ratcliffe, and L. Roz Detecting lung cancer in plasma with the use of multiple genetic markers Int J Cancer 108 2004 91 96
44. E. Tagliabue, R. Agresti, M.L. Carcangiu, C. Ghirelli, D. Morelli, and M. Campiglio Role of HER2 in wound-induced breast carcinoma proliferation Lancet 362 9383 2003 527 533
45. W.P. Carney, R. Neumann, A. Lipton, K. Leitzel, S. Ali, and C.P. Price Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer Clin Chem 49 10 2003 1579 1598
46. V. Muller, C. Thomssen, C. Karakas, I. Eustermann, J. Ramirez Porras, and C. Coith Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay Int J Biol Markers 18 1 2003 13 20
47. M. Krainer, T. Brodowicz, R. Zeillinger, C. Wiltschke, C. Scholten, and E. Seifert Kubista Tissue expression and serum levels of HER-2/neu in patients with breast cancer Oncology 54 1997 475 481
48. Y. Tsuchida, and P. Therasse Response evaluation criteria in solid tumors (RECIST): new guidelines Med Pediatr Oncol 37 1 2001 1 3
49. A. Van Dalen, V. Barak, A. Cremaschi, M. Gion, R. Molina, and M. Namer The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease Int J Biol Markers 13 1 1998 10 15
50. G. Gasparini, and M. Gion Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints Cancer J Sci Am 6 2000 117 131
51. Y. Tong, X. Liu-Chen, E.A. Ercikan-Abali, G.M. Capiaux, S.C. Zhao, and D. Banerjee Isolation and characterization of thymitaq (AG337) and 5-fluoro-2-deoxyuridylate-resistant mutants of human thymidylate synthase from ethyl methanesulfonate-exposed human sarcoma HT1080 cells J Biol Chem 273 19 1998 11611 11618
52. W.H. Lewis, and P.R. Srinivasan Chromosome-mediated gene transfer of hydroxyurea resistance and amplification of ribonucleotide reductase activity Mol Cell Biol 3 6 1983 1053 1061
53. M.T. Kuo, S. Sen, W.N. Hittelman, and T.C. Hsu Chromosomal fragile sites and DNA amplification in drug-resistant cells Biochem Pharmacol 56 1 1998 7 13
54. E. Weisberg, and J.D. Griffin Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines Blood 95 11 2000 3498 3505
55. T. Udagawa, A. Fernandez, E.G. Achilles, J. Folkman, and R.J. D'Amato Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy FASEB J 16 11 2002 1361 1370
56. Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, and R.K. Jain Tumour biology: herceptin acts as an anti-angiogenic cocktail Nature 416 6878 2002 279 280
57. A. Viloria-Petit, T. Crombet, S. Jothy, D. Hicklin, P. Bohlen, and J.M. Schlaeppi Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 13 2001 5090 5101
58. M. Gion Serum tumour markers: from quality control to total quality management The Breast 9 6 2000 306 311
59. C. Sturgeon Limitations of assay techniques for tumor markers E.P. Diamandis H.A. Fritsche H. Lilja D.W. Chan M.K. Schwartz Tumor markers: physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington, DC 65 82
60. A. Forslund, U. Kressner, C. Lonnroth, M. Andersson, G. Lindmark, and K. Lundholm P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH Int J Oncol 21 2 2002 409 415
61. M.F. Press, G. Hung, W. Godolphin, and D.J. Slamon Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Cancer Res 54 1994 2771 2777
62. R. Dittadi, S. Meo, B. Amoroso, and M. Gion Detection of different estrogen receptor forms in breast cancer cytosol by enzyme immunoassay Cancer Res 57 1997 1066 1072
63. W. Shao, and M. Brown Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy Breast Cancer Res 6 1 2004 39 52 Epub 2003 Nov 07
64. D. Coradini, M.G. Daidone, and P. Boracchi Time-dependent relevance of steroid receptors in breast cancer J Clin Oncol 18 2000 2702 2709
65. P.S. Hupperets, L. Volovics, and L.J. Schouten The prognostic significance of steroid receptor activity in tumor tissue of patients with primary breast cancer Am J Clin Oncol 20 1997 546 551
66. G. Gasparini, and M. Toi Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 89 1997 139 147
67. R. Dittadi, and M. Gion More about: prognostic importance of low c-erbB2 expression in breast tumors J Natl Cancer Inst 92 2000 1443
68. M. Gion, P. Boracchi, R. Dittadi, E. Biganzoli, L. Peloso, and R. Mione Prognostic role of serum CA15.3 in 362 node negative breast cancer. An old player for a new game Eur J Cancer 38 2002 1181 1188
69. D. Coradini, E. Biganzoli, and P. Boracchi Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation Int J Cancer 79 1998 305 311
70. D.G. Altman, B. Lausen, W. Sauerbrei, and M. Schumacher Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829 835
71. E. Biganzoli, P. Boracchi, M.G. Daidone, M. Gion, and E. Marubini Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers Int J Biol Markers 13 3 1998 107 123
72. D.G. Altman, B.L. De Stavola, S.B. Love, and K.A. Stepniewska Review of survival analyses published in cancer journals Br J Cancer 72 1995 511 518
73. T.J. O'Leary Standardization in immunohistochemistry Appl Immunohistochem Mol Morphol 9 1 2001 3 8
74. P. Salven, A. Orpana, and H. Joensuu Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor Clin Cancer Res 5 1999 487 491
75. R. Dittadi, S. Meo, and F. Fabris Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments Int J Biol Markers 16 2001 87 96
76. R.T. Poon, S.T. Fan, and J. Wong Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 2001 1207 1225
77. D. Moher CONSORT: an evolving tool to help improve the quality of reports of randomized trials JAMA 279 1998 1489 1491
78. R. Horton Medical editors trial amnesty: unreported trial registration form Lancet 350 1997 756 757
79. J.A. Knottnerus, C. van Weel, and J.W. Muris Evaluation of diagnostic procedures BMJ 324 7335 2002 477 480
80. D.F. Hayes, R.C. Bast, and C.E. Desch Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers J Natl Cancer Inst 88 1996 1456 1466
81. M. Gion, P. Boracchi, E. Biganzoli, and M.G. Daidone A guide for reviewing submitted manuscripts and indications for the design of translational research studies on biomarkers Int J Biol Markers 13 1999 123 133
82. P.M. Bossuyt, J.B. Reitsma, D.E. Bruns, C.A. Gatsonis, P.P. Glasziou, and L.M. Irwig Standards for reporting of diagnostic accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative Clin Biochem 36 1 2003 2 7
83. D.F. Ranshoff Developing molecular biomarkers for cancer Science 299 2003 1679 1681
84. D. Palmer-Toy, S. Kuzdal, and D.W. Chan Proteomic approaches to tumor marker discovery E.P. Diamandis H.A. Fritsche H. Lilja D.W. Chan M.K. Schwartz Tumor markers: physiology, pathobiology, technology, and clinical applications 2002 AACC Press Washington, DC 400 409
85. E.P. Diamandis Point: proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 49 2003 1272 1275
86. B.L. Adam, Y. Qu, J.W. Davis, M.D. Ward, M.A. Clements, and L.H. Cazares Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men Cancer Res 62 13 2002 3609 3614
87. Y. Qu, B.L. Adam, Y. Yasui, M.D. Ward, L.H. Cazares, and P.F. Schellhammer Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients Clin Chem 48 10 2002 1835 1843
88. E. Petricoin 3rd, and L.A. Liotta Counterpoint: the vision for a new diagnostic paradigm Clin Chem 49 8 2003 1276 1278